NEW YORK, NY -- (Marketwired) -- 06/20/14 -- Nuvilex, Inc. (OTCQB: NVLX) can accomplish more in its upcoming preclinical trials than many may realize. With the announcement that Translational Drug Development (TD2) will be conducting the preclinical studies and clinical trials that will follow to study the Maryland biotech's pancreatic cancer treatment and its ability to relieve symptoms associated with the deadly cancer, Nuvilex entered into a high profile opportunity.
TD2 is considered by many to be the premiere Contract Research Organization (CRO) in the country when it comes to oncology studies and trials, so when Nuvilex begins its preclinicals, you can bet Cell-in-a-Box® will be front and center, and for the first time ever, it will get the true attention it deserves.
While most of the company's investors are waiting on late phase clinical trials in advanced pancreatic cancer to begin, the company stated it would be entering into another area of research in pancreatic cancer as well -- to relieve the unbearable pain associated with the cancer and to slow the onset and build-up of ascites fluid caused by pancreatic cancer and other abdominal cancers in the abdominal cavity.
This exposure for Nuvilex and the company's treatment of Cell-in-a-Box® combined with the anticancer drug ifosfamide will be invaluable. TD2 is a world-class drug development service, specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible. Additionally, the firm is associated with the Pancreatic Cancer Research Team (PCRT) which gives Nuvilex access to the world's clinical experts in pancreatic cancer.
TD2's work garners a great deal of attention, and its results are well documented. This is likely due to the fact that the Scottsdale, Arizona, CRO and the PCRT are made up of some of the most well-known names in oncology.
The PCRT was created by world-renowned pancreatic cancer experts Dr. Daniel Von Hoff and Dr. Manuel Hidalgo. The consortium of experts is a premiere resource for biotech and pharmaceutical companies looking to develop new agents for patients with pancreatic cancer. This network provides the world's most coordinated effort dedicated to rapidly translating research discoveries into new treatments and supportive care.
And, one has to believe that if the Cell-in-a-Box®/ifosfamide combination can prove itself to such an impressive and influential group of clinicians, word will spread quickly of its potential. It could very well be this exposure that draws even greater interest to Nuvilex's treatment, its late phase clinical trials and the catalyst behind forming potential relationships and partnerships that could allow the company to get an effective pancreatic treatment to market in expedited fashion.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Nuvilex content by a third party who reserves the right to buy, sell or remain neutral on securities after the publication of this article. SMMG has received total compensation of $99,700 for all created content related to Nuvilex. Additionally, a principal at SMMG currently owns 200,000 total shares of Nuvilex issued by the company through a consulting agreement which has since ended for work unrelated to content development. All shares have been held for the requisite period under Rule 144 as of April 30, 2014, and are eligible to be sold immediately without further notice. For more information: www.stockmarketmediagroup.com.